Eli Lilly & Co said on Monday its oral weight-loss drug Foundayo reduced breathing interruptions by up to 44% in a late-stage sleep apnea trial. Shares of the drugmaker rose 3% following the announcement. The data strengthens Lilly's lead in sleep apnea treatment after its injectable medicine Zepbound gained approval.
